Vivek Subbiah, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute, shared on LinkedIn:
“Engaging discussion with Saheli Sadanand the amazing Deputy Editor at Nature Medicine
I made the case: This is a terrific time in oncology research. AI is accelerating insights. Precision medicine is personalizing care. Drug development is defying limits. We have challenges in real world implementation.
Journals like Nature, Nature Medicine Nature Magazine must keep leading and prioritizing oncology, amplifying breakthroughs, & shaping the future of care.
Thanks Saheli for listening to my pitch and sharing the vision for Oncology.”
More posts featuring Vivek Subbiah.